# Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

> **NCT05263895** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Bioavailability

## Interventions

- **DRUG:** PF-07321332/ritonavir
- **DRUG:** PF-07321332/ritonavir
- **DRUG:** PF-07321332/ritonavir
- **DRUG:** PF-07321332/ritonavir
- **DRUG:** PF-07321332

## Key facts

- **NCT ID:** NCT05263895
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-03
- **Primary completion:** 2022-05-16
- **Final completion:** 2022-05-16
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263895, "Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05263895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*